Michael Charlton to Hepatitis C, Chronic
This is a "connection" page, showing publications Michael Charlton has written about Hepatitis C, Chronic.
Connection Strength
8.814
-
International Liver Transplantation Society Asian Consensus on the Management of Hepatitis C Virus Infection in Resource Limited Setting-From Noncirrhotic to Decompensated Disease and After Liver Transplantation. Transplantation. 2019 04; 103(4):733-746.
Score: 0.617
-
Changes in the Prevalence of Hepatitis C Virus Infection, Nonalcoholic Steatohepatitis, and Alcoholic Liver Disease Among Patients With Cirrhosis or Liver Failure on the Waitlist for Liver Transplantation. Gastroenterology. 2017 04; 152(5):1090-1099.e1.
Score: 0.529
-
Sofosbuvir and Velpatasvir for Patients with HCV Infection. N Engl J Med. 2016 04 28; 374(17):1688.
Score: 0.504
-
Response to Fibrosis progression in patients treated for hepatitis C recurrence. Liver Int. 2015 Dec; 35(12):2625.
Score: 0.490
-
A clinician's guide to drug-drug interactions with direct-acting antiviral agents for the treatment of hepatitis C viral infection. Hepatology. 2016 Feb; 63(2):634-43.
Score: 0.483
-
Impact of fibrosis progression on clinical outcome in patients treated for post-transplant hepatitis C recurrence. Liver Int. 2015 Nov; 35(11):2433-41.
Score: 0.476
-
Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease. Gastroenterology. 2015 Sep; 149(3):649-59.
Score: 0.472
-
Interleukin-28B and fibrosing cholestatic hepatitis in posttransplant hepatitis C: a case-control study and literature review. Liver Transpl. 2013 Dec; 19(12):1311-7.
Score: 0.427
-
Victory and defeat at Heraclea - treating hepatitis C infection following liver transplantation with telaprevir and boceprevir. J Hepatol. 2014 Jan; 60(1):6-8.
Score: 0.423
-
Recipient IL28B polymorphism is an important independent predictor of posttransplant diabetes mellitus in liver transplant patients with chronic hepatitis C. Am J Transplant. 2012 Mar; 12(3):737-44.
Score: 0.376
-
Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection. Hepatology. 2011 Jan; 53(1):317-24.
Score: 0.348
-
Insulin resistance, serum adipokines and risk of fibrosis progression in patients transplanted for hepatitis C. Am J Transplant. 2009 Jun; 9(6):1406-13.
Score: 0.311
-
Impact of obesity on treatment of chronic hepatitis C. Hepatology. 2006 Jun; 43(6):1177-86.
Score: 0.254
-
Natural history and management of hepatitis C infection after liver transplantation. Semin Liver Dis. 2004; 24 Suppl 2:79-88.
Score: 0.215
-
Efficacy and Safety of Sofosbuvir/Velpatasvir Plus Ribavirin in Patients with Hepatitis C Virus-Related Decompensated Cirrhosis. Viruses. 2023 09 29; 15(10).
Score: 0.211
-
Natural history of hepatitis C and outcomes following liver transplantation. Clin Liver Dis. 2003 Aug; 7(3):585-602.
Score: 0.208
-
The impact of advancing donor age on histologic recurrence of hepatitis C infection: the perils of ignored maternal advice. Liver Transpl. 2003 May; 9(5):535-7.
Score: 0.205
-
Treatment of posttransplantation recurrence of hepatitis C with interferon and ribavirin: lessons on tolerability and efficacy. Liver Transpl. 2002 Jul; 8(7):623-9.
Score: 0.193
-
Increasing Utilization and Excellent Initial Outcomes Following Liver Transplant of Hepatitis C Virus (HCV)-Viremic Donors Into HCV-Negative Recipients: Outcomes Following Liver Transplant of HCV-Viremic Donors. Hepatology. 2019 06; 69(6):2381-2395.
Score: 0.155
-
Improved Graft Survival After Liver Transplantation for Recipients With Hepatitis C Virus in the Direct-Acting Antiviral Era. Liver Transpl. 2019 04; 25(4):598-609.
Score: 0.154
-
Baseline Factors Associated With Improvements in Decompensated Cirrhosis After Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection. Gastroenterology. 2018 06; 154(8):2111-2121.e8.
Score: 0.143
-
Sofosbuvir and Velpatasvir Combination Improves Patient-reported Outcomes for Patients With HCV Infection, Without or With Compensated or Decompensated Cirrhosis. Clin Gastroenterol Hepatol. 2017 03; 15(3):421-430.e6.
Score: 0.131
-
Patient-reported outcomes with sofosbuvir and velpatasvir with or without ribavirin for hepatitis C virus-related decompensated cirrhosis: an exploratory analysis from the randomised, open-label ASTRAL-4 phase 3 trial. Lancet Gastroenterol Hepatol. 2016 10; 1(2):122-132.
Score: 0.128
-
On-treatment HCV RNA in patients with varying degrees of fibrosis and cirrhosis in the SOLAR-1 trial. Antivir Ther. 2016; 21(6):541-546.
Score: 0.124
-
Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. N Engl J Med. 2015 Dec 31; 373(27):2618-28.
Score: 0.122
-
Prevalence and clinical consequences of Hepatitis E in patients who underwent liver transplantation for chronic Hepatitis C in the United States. BMC Infect Dis. 2015 Sep 02; 15:371.
Score: 0.120
-
Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation. Hepatology. 2015 May; 61(5):1485-94.
Score: 0.117
-
Broadly neutralizing antibodies abrogate established hepatitis C virus infection. Sci Transl Med. 2014 Sep 17; 6(254):254ra129.
Score: 0.113
-
Comparative effectiveness of telaprevir-based triple therapy in patients with chronic hepatitis C. Mayo Clin Proc. 2014 May; 89(5):595-601.
Score: 0.109
-
The changing epidemiology of hepatitis C virus infection in the United States: National Health and Nutrition Examination Survey 2001 through 2010. J Hepatol. 2014 Apr; 60(4):691-8.
Score: 0.107
-
Introduction to the genetics and biology of interleukin-28B. Hepatology. 2012 Jul; 56(1):361-6.
Score: 0.097
-
Single- and multiple-ascending-dose studies of the NS3 protease inhibitor asunaprevir in subjects with or without chronic hepatitis C. Antimicrob Agents Chemother. 2012 Apr; 56(4):1838-44.
Score: 0.094
-
A randomized, multicenter study comparing steroid-free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C. Liver Transpl. 2011 Dec; 17(12):1394-403.
Score: 0.093
-
Impact of depressive symptoms and their treatment on completing antiviral treatment in patients with chronic hepatitis C. J Clin Gastroenterol. 2010 Sep; 44(8):e178-85.
Score: 0.085
-
Perioperative viral kinetics: new insights or the Emperor's new clothes? Liver Transpl. 2006 Feb; 12(2):194-5.
Score: 0.062
-
Early detection of hepatitis C allograft reinfection after orthotopic liver transplantation: a molecular and histologic study. Mod Pathol. 2000 Mar; 13(3):229-37.
Score: 0.041
-
Clinical significance of TT virus infection in patients with chronic hepatitis C. Am J Gastroenterol. 1999 Oct; 94(10):3020-7.
Score: 0.040
-
The clinical significance of simultaneous infection with hepatitis G virus in patients with chronic hepatitis C. Am J Gastroenterol. 1999 Apr; 94(4):1000-5.
Score: 0.039